Open access

A plasma‐based protein signature combining NPTXR, ACHE, and p‐tau217 predicts progression to symptomatic Alzheimer's disease

Menghan Liu Katherine Gong Yike Chen G. Heo Ying Xu J. Timsina D. Western J. Budde J. Morris Giorgetti Marco David M. Holtzman J. Hinson Scott Levin N. Ashton Marisa N. Denkinger Suzanne E. Schindler Kausik Das Muhammad Ali C. Cruchaga

Aug 2026 · Alzheimer's & Dementia · Vol 22 · 0 citations · 40 references

Medicine

TL;DR

Whether these proteins, alone or combined with plasma phosphorylated tau 217 (p‐tau217), predict progression from cognitively unimpaired to symptomatic AD is evaluated.

Abstract

We recently identified a plasma‐based seven‐protein model with strong performance for Alzheimer's disease (AD) classification. Here, we evaluated whether these proteins, alone or combined with plasma phosphorylated tau 217 (p‐tau217), predict progression from cognitively unimpaired to symptomatic AD.

DOI PubMed Semantic Scholar

Read PDF

Similar papers

Open access Aug 2026

Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer's disease across diverse participants

Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown.

Y. Piura, P. Aduen, Leah Schecter et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Plasma P‐tau217 for detecting amyloid clearance after donanemab in Alzheimer's disease

This analysis of the phase 3 TRAILBLAZER‐ALZ 2 trial examined whether plasma tau protein phosphorylated at threonine 217 (p‐tau217) level can reliably monitor treatment‐related amyloid clearance (TRAC) after donanemab treatment in early symptomatic Alzheimer's disease (AD).

Emily C. Collins, M. Lu, Rose C. Beck et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Plasma p‐tau217 detects Alzheimer's disease co‐pathology in cerebral amyloid angiopathy: Comparison to CSF biomarkers in the ANGMAR cohort

Cerebral amyloid angiopathy (CAA) frequently co‐occurs with Alzheimer's disease (AD), generating mixed vascular–neurodegenerative phenotypes. Plasma phosphorylated tau (p‐tau)217 is a robust biomarker of AD, but its performance in CAA remains unclear.

A. Fernández-Lebrero, J. Jiménez-Balado, G. García‐Escobar et al. · Alzheimer's & Dementia · 0 citations

Open access Jul 2026

Heterogeneity in plasma p‐tau217 response and its association with cognitive trajectories under lecanemab treatment

Plasma phosphorylated tau 217 (p‐tau217) is a promising biomarker for monitoring treatment response in Alzheimer's disease (AD), but its longitudinal dynamics and clinical relevance remain unclear.

Sung-Hoon Kang, Yu Jeong Park, Seung-Yun Lee et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Predicting continuous amyloid PET levels with CSF and plasma brain‐derived p‐tau217

Staging amyloid beta (Aβ) burden along a continuous spectrum provides clinically relevant information. Conventional phosphorylated tau (p‐tau)217 reliably identifies amyloid positron emission tomography (PET) positivity, but its ability to capture the full Aβ continuum is limited. Recently developed brain‐derived (BD) p‐tau217 assays enrich for central nervous system tau species and may improve specificity.

Lydia Trudel, J. Therriault, Arthur C. Macedo et al. · Alzheimer's & Dementia · 0 citations

Open access Aug 2026

Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer's disease through machine learning and transcriptomic integration

Functional brain network alterations associated with Alzheimer's disease (AD) pathology, including amyloid beta (Aβ) and phosphorylated tau (p‐tau), are difficult to interpret due to overlapping aging‐associated and non‐amyloid biological processes.

K. Zhao, Hua Xie, Tovia Jacobs et al. · Alzheimer's & Dementia · 0 citations